Evolus expects sustained adjusted EBITDA profitability beginning in 2026
EOLS•Evolus expects sustained adjusted EBITDA profitability beginning in 2026, with funding in place to reach that goal. Revenue was $297.2 million in 2025, up from $266.3 million in 2024.
1. Profitability outlook
Evolus said it expects sustained adjusted EBITDA profitability beginning in 2026 and has funding in place to reach that goal. Revenue reached $297.2 million in 2025, up from $266.3 million in 2024, marking six consecutive years of double-digit growth. The company expects U.S. approval of Evolysse Sculpt by year-end 2026 and is targeting year-end 2027 for Evolysse Lips.
